Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.

Yin RX, Yang DZ, Wu JZ.

Theranostics. 2014 Jan 8;4(2):175-200. doi: 10.7150/thno.7210. eCollection 2014. Review.

2.

Local delivery of therapeutics for percutaneous coronary intervention.

Kennedy KL, Lucas AR, Wan W.

Curr Drug Deliv. 2011 Sep;8(5):534-56.

PMID:
21696350
3.

Drug-eluting stents.

García-García HM, Vaina S, Tsuchida K, Serruys PW.

Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Review.

PMID:
17091802
4.

Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.

5.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
6.

Novel approaches to reduce restenosis.

Beyar R.

Ann N Y Acad Sci. 2004 May;1015:367-78. Review.

PMID:
15201175
7.

Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.

Adriaenssens T, Dens J, Ughi G, Coosemans M, Onsea K, Dubois C, Sinnaeve P, Vrolix M, Desmet W.

EuroIntervention. 2011 May;7 Suppl K:K100-5. doi: 10.4244/EIJV7SKA17.

PMID:
22027717
8.

Nanoparticulate carriers for the treatment of coronary restenosis.

Brito L, Amiji M.

Int J Nanomedicine. 2007;2(2):143-61. Review.

9.

Drug-eluting stent: the emerging technique for the prevention of restenosis.

Sheiban I, Carrieri L, Catuzzo B, Destefanis P, Oliaro E, Moretti C, Trevi GP.

Minerva Cardioangiol. 2002 Oct;50(5):443-53. Review.

PMID:
12384626
10.

Eluting combination drugs from stents.

Thipparaboina R, Khan W, Domb AJ.

Int J Pharm. 2013 Sep 15;454(1):4-10. doi: 10.1016/j.ijpharm.2013.07.005. Epub 2013 Jul 10. Review.

PMID:
23850234
11.

Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.

Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT, Chetcuti SJ, Bates ER, Gurm HS.

Am J Cardiol. 2007 May 15;99(10):1399-402. Epub 2007 Apr 4.

PMID:
17493468
12.

Restenosis related to percutaneous coronary intervention has been solved?

Kivelä A, Hartikainen J.

Ann Med. 2006;38(3):173-87. Review.

PMID:
16720432
13.

Paclitaxel-eluting balloon: from bench to bed.

De Labriolle A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R.

Catheter Cardiovasc Interv. 2009 Apr 1;73(5):643-52. doi: 10.1002/ccd.21895. Review.

PMID:
19309715
14.

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.

Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ.

Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240.

15.

Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.

Nishihira K, Shibata Y, Ishikawa T, Nomura K, Nakama T, Mine D, Inoue Y, Ashikaga K, Kuriyama N, Matsuyama A, Imamura T, Asada Y, Kitamura K.

Circ J. 2010 Nov;74(11):2329-33. Epub 2010 Sep 28.

16.

Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.

PMID:
22954234
17.

Restenosis after PCI. Part 2: prevention and therapy.

Jukema JW, Ahmed TA, Verschuren JJ, Quax PH.

Nat Rev Cardiol. 2011 Oct 11;9(2):79-90. doi: 10.1038/nrcardio.2011.148. Review.

PMID:
21989052
18.

Coronary drug-eluting stents: from design optimization to newer strategies.

Sun D, Zheng Y, Yin T, Tang C, Yu Q, Wang G.

J Biomed Mater Res A. 2014 May;102(5):1625-40. doi: 10.1002/jbm.a.34806. Epub 2013 Jul 1. Review.

PMID:
23703913
19.

Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.

Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2008 Apr 1;71(5):594-8. doi: 10.1002/ccd.21399.

PMID:
18311841
20.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384

Supplemental Content

Support Center